Bonus Episode
FLT3 Mutations in Patients with AML
This episode, sponsored by Novartis, features Prof Adriano Venditti, Associate Professor, Haematology, University of Rome Tor Vergata and Prof Lars Bullinger, Department of Haematology, Oncology and Tumour Immunology, Charité University Medicine. Together, they discuss the treatment of patients who have acute myeloid leukemia (AML) as well as FMS-like tyrosine kinase 3 gene (FLT3) mutations.
Download MP3 (mp 33:02 mins)
